Literature DB >> 2962217

Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

D R Thomas1, D R Nelson, A M Johnson.   

Abstract

Paroxetine was shown to be a potent (Ki = 1.1 nM) and specific inhibitor of [3H]-5-hydroxytryptamine (5-HT) uptake into rat cortical and hypothalamic synaptosomes in vitro. Lineweaver-Burk kinetic analysis determined that this inhibition was competitive in nature, implying a direct interaction with the 5-HT uptake transporter complex. Oral administration of paroxetine produced a dose-related inhibition of [3H]-5-HT uptake (ED50 = 1.9 mg/kg) into rat hypothalamic synaptosomes ex vivo with little effect on [3H]-l-noradrenaline (NA) uptake (ED50 greater than 30 mg/kg). This selectivity for 5-HT uptake was maintained after oral dosing for 14 days. Paroxetine (ED50 1-3 mg/kg PO) prevented the 5-HT depleting effect of p-chloroamphetamine (PCA) in rat brain, demonstrating 5-HT uptake blockade in vivo. Radioligand binding techniques in rat brain in vitro showed that paroxetine has little affinity for alpha 1, alpha 2 or beta adrenoceptors, dopamine (D2), 5-HT1, 5-HT2 or histamine (H1) receptors at concentrations below 1000 nM. Paroxetine demonstrated weak affinity for muscarinic receptors (Ki = 89 nM) but was at least 15 fold weaker than amitriptyline (Ki = 5.1 nM). Paroxetine, therefore, provides a useful pharmacological tool for investigating 5-HT systems and furthermore should be an antidepressant with reduced tricyclic-like side-effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2962217     DOI: 10.1007/bf00179933

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  (Z)-dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl) propene (h 102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake.

Authors:  S B Ross; S O Ogren; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-08

2.  Potent and long-lasting potentiation of two 5-hydroxytryptophan- induced effects in mice by three selective 5-ht uptake inhibitors.

Authors:  J B Lassen
Journal:  Eur J Pharmacol       Date:  1978-02-01       Impact factor: 4.432

3.  A comparison of the effect of paroxetine and amitriptyline on the tyramine pressor response test.

Authors:  S M Hassan; G Wainscott; P Turner
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

4.  A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine.

Authors:  D T Wong; J S Horng; F P Bymaster; K L Hauser; B B Molloy
Journal:  Life Sci       Date:  1974-08-01       Impact factor: 5.037

5.  High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes.

Authors:  E T Mellerup; P Plenge; M Engelstoft
Journal:  Eur J Pharmacol       Date:  1983-12-23       Impact factor: 4.432

6.  Pre-treatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment.

Authors:  J W Maas; J H Kocsis; C L Bowden; J M Davis; D E Redmond; I Hanin; E Robins
Journal:  Psychol Med       Date:  1982-02       Impact factor: 7.723

7.  Influence of the new 5-HT-uptake inhibitor paroxetine on hypermotility in rats produced by p-chloroamphetamine (PCA) and 4,alpha-dimethyl-7-tyramine (H 77/77).

Authors:  J B Lassen
Journal:  Psychopharmacology (Berl)       Date:  1978-04-28       Impact factor: 4.530

8.  Review of the animal pharmacology and pharmacokinetics of fluvoxamine.

Authors:  V Claassen
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

9.  Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors.

Authors:  D T Wong; F P Bymaster; L R Reid; P G Threlkeld
Journal:  Biochem Pharmacol       Date:  1983-04-01       Impact factor: 5.858

10.  An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness.

Authors:  C Børup; B Meidahl; I M Petersen; A Vangtorp; P le Fèvre Honoré
Journal:  Pharmacopsychiatria       Date:  1982-11
View more
  54 in total

1.  Modulation of frontostriatal interaction aligns with reduced primary reward processing under serotonergic drugs.

Authors:  Birgit Abler; Georg Grön; Antonie Hartmann; Coraline Metzger; Martin Walter
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

2.  The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.

Authors:  Aloke K Dutta; Bhaskar Gopishetty; Sanjib Gogoi; Solav Ali; Juan Zhen; Maarten Reith
Journal:  Eur J Pharmacol       Date:  2011-09-24       Impact factor: 4.432

3.  A case of neurotoxic syndrome with the use of long-acting risperidone and subsequent olanzapine and paroxetine.

Authors:  Rahul S Bharadwaj; Teresa B Slade
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  Synthesis, in vitro binding studies and docking of long-chain arylpiperazine nitroquipazine analogues, as potential serotonin transporter inhibitors.

Authors:  Małgorzata Jarończyk; Karol Wołosewicz; Mari Gabrielsen; Gabriel Nowak; Irina Kufareva; Aleksander P Mazurek; Aina W Ravna; Ruben Abagyan; Andrzej J Bojarski; Ingebrigt Sylte; Zdzisław Chilmonczyk
Journal:  Eur J Med Chem       Date:  2012-01-15       Impact factor: 6.514

5.  Drug inhibition indicates a single-site model of the 5-HT uptake site/antidepressant binding site in rat and human brain.

Authors:  J O Marcusson; A Andersson; I Bäckström
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 6.  Pharmacologic treatment of depression in late life.

Authors:  A J Flint
Journal:  CMAJ       Date:  1997-10-15       Impact factor: 8.262

7.  Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine.

Authors:  E Le Poul; N Laaris; E Doucet; A M Laporte; M Hamon; L Lanfumey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

Review 8.  Paroxetine controlled release.

Authors:  Lynne M Bang; Gillian M Keating
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test.

Authors:  Mehdi Ghasemi; Laleh Montaser-Kouhsari; Hamed Shafaroodi; Behtash Ghazi Nezami; Farzad Ebrahimi; Ahmad Reza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2009-07-16       Impact factor: 4.530

Review 10.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.